CABA
- Cabaletta Bio, Inc.
()
Overview
Company Summary
Cabaletta Bio, Inc. is a biopharmaceutical company that specializes in developing gene therapies to treat rare diseases. Their primary focus is on developing therapies that target B-cell-mediated autoimmune diseases, where the body's immune system mistakenly attacks its own cells.
Cabaletta Bio's proprietary technology platform, called The Cabaletta Approach, enables them to engineer chimeric autoantibody receptor (CAAR) T cells, which are designed to selectively bind and eliminate disease-causing B cells. These CAAR T cells are engineered to recognize specific proteins expressed on the surface of B cells, leading to their targeted destruction and subsequent modulation of the autoimmune response.
The company's innovative approach holds great promise in treating diseases with limited or no effective treatment options, including rare autoimmune diseases such as mucosal pemphigus vulgaris (mPV) and mucous membrane pemphigoid (MMP), which are potentially debilitating conditions.
Cabaletta Bio aims to bring meaningful improvement to the lives of patients suffering from these diseases by developing and commercializing transformative gene therapies. They are actively engaged in conducting clinical trials to evaluate the safety and efficacy of their therapies and are devoted to advancing their pipeline to address a broader range of autoimmune diseases.
By leveraging their expertise in gene therapy and focusing on targeted treatments, Cabaletta Bio aspires to revolutionize the way rare autoimmune diseases are managed, providing new hope and therapeutic options to patients who have limited treatment options or are currently underserved by existing therapies.